ExoStat Medical, Inc.

✔️ ExoStat Medical is a privately-owned medical device company headquartered in Prior Lake, Minnesota. ✔️ ExoStat has developed breakthrough technology in a novel device, the MicroTREND System ("MicroTREND"), that is the first to monitor the partial pressure of carbon dioxide ("pCO2") in microcirculatory oral mucosal tissue. ✔️ It is well established and clinically demonstrated that rising levels of pCO2 are a recognized indicator of impaired oxygen delivery and inadequate tissue perfusion. ✔️ All forms of shock – including those caused by infection or trauma – result in microcirculatory hypoperfusion, which is primarily due to reduced blood flow. ✔️ The oral cavity is a uniquely ideal site from which to evaluate systemic tissue perfusion due to its vascularity and connectivity characteristics. This tissue (mucosa) is readily permeable to carbon dioxide ("CO2") and less so to other gases, such as oxygen ("O2"). ✔️ It has been proven that when mucosa is under-perfused (inadequate blood flow and oxygenation), pCO2 levels rise quickly. This increase in pCO2 occurs throughout the entire gastro-intestinal tract (the "GI Tract"), including the buccal tissue (POMCO2) in the mouth. ✔️ The MicroTREND can capture this POMCO2 trend line in real-time for up to four hours per disposable sensor in a non-invasive manner. ✔️ Current markers of macrocirculatory tissue perfusion, like blood pressure and pulse oximetry, fail to provide real-time data relative to microcirculatory hemodynamic stability. This is due to adaptive bodily mechanisms that sustain macrocirculatory blood flow despite the manifestation of microcirculatory dysfunction. ✔️ The MicroTREND is the only sensor that measures non-invasively the real-time status of microcirculation at the bedside. ✔️ The MicroTREND received its 510(k) clearance from the FDA in November 2024.

• Employees 8
• Annual Revenue $22031000
• Total Funding $1865200